Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811) — Working Capital to Net Assets Ratio
Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811) has a Working Capital to Net Assets ratio of 9.1% as of September 2025. Working capital of CN¥121.19 Million (current assets of CN¥396.18 Million minus current liabilities of CN¥274.99 Million) is measured against net assets of CN¥1.33 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See debt-free asset ratio of Zhejiang Cheng Yi Pharmaceutical Co Ltd to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Zhejiang Cheng Yi Pharmaceutical Co Ltd Working Capital to Net Assets (2011–2024)
This chart shows how Zhejiang Cheng Yi Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2011 to 2024. As of September 2025, the ratio stands at 9.1%, reflecting working capital of CN¥121.19 Million against net assets of CN¥1.33 Billion CNY. Check Zhejiang Cheng Yi Pharmaceutical Co Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Zhejiang Cheng Yi Pharmaceutical Co Ltd (2011–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Zhejiang Cheng Yi Pharmaceutical Co Ltd from 2011 to 2024, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811) total market value.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 8.1% | CN¥102.12 Million | CN¥1.27 Billion | CN¥393.62 Million | CN¥291.50 Million | ▼ -6.5 pp |
| 2023 | 14.6% | CN¥174.78 Million | CN¥1.20 Billion | CN¥517.42 Million | CN¥342.65 Million | ▼ -1.8 pp |
| 2022 | 16.4% | CN¥178.85 Million | CN¥1.09 Billion | CN¥436.84 Million | CN¥257.99 Million | ▲ +12.3 pp |
| 2021 | 4.1% | CN¥40.93 Million | CN¥998.88 Million | CN¥287.80 Million | CN¥246.87 Million | ▼ -2.1 pp |
| 2020 | 6.2% | CN¥54.93 Million | CN¥886.09 Million | CN¥282.31 Million | CN¥227.38 Million | ▼ -8.8 pp |
| 2019 | 15.0% | CN¥114.98 Million | CN¥768.96 Million | CN¥317.18 Million | CN¥202.20 Million | ▼ -15.7 pp |
| 2018 | 30.6% | CN¥206.25 Million | CN¥673.54 Million | CN¥343.82 Million | CN¥137.57 Million | ▼ -35.5 pp |
| 2017 | 66.1% | CN¥396.34 Million | CN¥599.57 Million | CN¥467.23 Million | CN¥70.88 Million | ▲ +30.7 pp |
| 2016 | 35.4% | CN¥99.25 Million | CN¥280.17 Million | CN¥181.00 Million | CN¥81.75 Million | ▲ +3.4 pp |
| 2015 | 32.0% | CN¥83.26 Million | CN¥259.92 Million | CN¥167.71 Million | CN¥84.45 Million | ▲ +5.0 pp |
| 2014 | 27.1% | CN¥66.85 Million | CN¥246.95 Million | CN¥147.96 Million | CN¥81.11 Million | ▲ +10.4 pp |
| 2013 | 16.6% | CN¥33.49 Million | CN¥201.40 Million | CN¥165.32 Million | CN¥131.83 Million | ▲ +0.8 pp |
| 2012 | 15.8% | CN¥28.19 Million | CN¥178.13 Million | CN¥207.54 Million | CN¥179.35 Million | ▲ +56.1 pp |
| 2011 | -40.3% | CN¥-41.34 Million | CN¥102.60 Million | CN¥151.22 Million | CN¥192.56 Million | — |